Merck restarts islatravir HIV treatment studies, but abandons monthly PrEP
European Commission approves first twice-yearly HIV medication
Second-line treatment nearly nine times more expensive than first-line in upper-middle income countries
Just six injections a year can prevent HIV: here’s what it will take for the world to afford them
ViiV Healthcare to allow 90 countries to access generic versions of HIV prevention shot
South Africa could be among the last to rollout child-friendly dolutegravir
NHS England is considering use of Descovy PrEP
Voluntary licensing via the Medicines Patent Pool is saving hundreds of thousands of lives
Trials of long-acting islatravir for HIV treatment and prevention placed on hold